0001209191-23-043998.txt : 20230801
0001209191-23-043998.hdr.sgml : 20230801
20230801163649
ACCESSION NUMBER: 0001209191-23-043998
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230728
FILED AS OF DATE: 20230801
DATE AS OF CHANGE: 20230801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: King Simona
CENTRAL INDEX KEY: 0001879312
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39231
FILM NUMBER: 231132315
MAIL ADDRESS:
STREET 1: C/O PASSAGE BIO, INC.
STREET 2: 2005 MARKET STREET, 39TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Passage BIO, Inc.
CENTRAL INDEX KEY: 0001787297
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822729751
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE COMMERCE SQUARE
STREET 2: 2005 MARKET STREET, 39TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
BUSINESS PHONE: 2678660312
MAIL ADDRESS:
STREET 1: ONE COMMERCE SQUARE
STREET 2: 2005 MARKET STREET, 39TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19103
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-28
0
0001787297
Passage BIO, Inc.
PASG
0001879312
King Simona
ONE COMMERCE SQUARE
2005 MARKET STREET, 39TH FLOOR
PHILADELPHIA
PA
19103
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-07-28
4
M
0
31250
0.00
A
35447
D
Common Stock
2023-07-28
4
S
0
11453
0.88
D
23994
D
Restricted Stock Units
2023-07-28
4
M
0
31250
0.00
D
Common Stock
31250
0
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer.
/s/ Edgar Cale, Attorney-in-Fact
2023-08-01